The Readout Loud
A podcast by STAT - Thursdays

Categories:
346 Episodes
-
342: FDA cuts, zombie biotechs, and too much weight loss?
Published: 2/20/2025 -
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Published: 2/13/2025 -
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
Published: 2/6/2025 -
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Published: 1/30/2025 -
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
Published: 1/23/2025 -
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
Published: 1/15/2025 -
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
Published: 1/9/2025 -
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
Published: 12/19/2024 -
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Published: 12/12/2024 -
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Published: 12/5/2024 -
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Published: 11/21/2024 -
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Published: 11/14/2024 -
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Published: 11/7/2024 -
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Published: 10/31/2024 -
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Published: 10/24/2024 -
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Published: 10/17/2024 -
326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
Published: 10/10/2024 -
325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO
Published: 10/3/2024 -
From Tradeoffs: Race to the Bottom
Published: 9/28/2024 -
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
Published: 9/26/2024
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.